MA31998B1 - Nouveaux derives d'insuline ayant un profil temps-action extremement retarde - Google Patents

Nouveaux derives d'insuline ayant un profil temps-action extremement retarde

Info

Publication number
MA31998B1
MA31998B1 MA32985A MA32985A MA31998B1 MA 31998 B1 MA31998 B1 MA 31998B1 MA 32985 A MA32985 A MA 32985A MA 32985 A MA32985 A MA 32985A MA 31998 B1 MA31998 B1 MA 31998B1
Authority
MA
Morocco
Prior art keywords
amino acid
radical
reaction time
insulin derivatives
new insulin
Prior art date
Application number
MA32985A
Other languages
Arabic (ar)
English (en)
Inventor
Paul Habermann
Gerhard Seipke
Roland Kurrle
Günter Müller
Mark Sommerfeld
Norbert Tennagels
Georg Tschank
Ulrich Werner
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40568276&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31998(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE200810003568 external-priority patent/DE102008003568A1/de
Priority claimed from DE200810025008 external-priority patent/DE102008025008A1/de
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA31998B1 publication Critical patent/MA31998B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de nouveaux analogues d'insuline à profil temporel/d'action basal, caractérisés en ce que a) la fin de chaîne b est composée d'un radical aminoacide basique amidé tel que lysine ou argininamide, b) le radical aminoacide n-terminal de la chaîne a de l'insuline est un radical lysine ou arginine, c) la position a8 de l'aminoacide est occupée par un radical histidine, d) la position a21 de l'aminoacide est occupée par un radical glycine, et e) une ou plusieurs substitutions et/ou additions de radicaux aminoacide chargés négativement ont eu lieu dans les positions a5, a15, a18, b-1, b0, b1, b2, b3 et b4.
MA32985A 2008-01-09 2010-07-05 Nouveaux derives d'insuline ayant un profil temps-action extremement retarde MA31998B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE200810003568 DE102008003568A1 (de) 2008-01-09 2008-01-09 Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US4465908P 2008-04-14 2008-04-14
DE200810025008 DE102008025008A1 (de) 2008-05-24 2008-05-24 Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
PCT/EP2009/000017 WO2009087081A2 (fr) 2008-01-09 2009-01-06 Nouveaux dérivés d'insuline à profil temporel/d'action extrêmement retardé

Publications (1)

Publication Number Publication Date
MA31998B1 true MA31998B1 (fr) 2011-01-03

Family

ID=40568276

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32985A MA31998B1 (fr) 2008-01-09 2010-07-05 Nouveaux derives d'insuline ayant un profil temps-action extremement retarde

Country Status (31)

Country Link
US (1) US9644017B2 (fr)
EP (1) EP2229407B1 (fr)
JP (1) JP5694779B2 (fr)
KR (1) KR20100111682A (fr)
CN (1) CN102007143B (fr)
AR (1) AR070118A1 (fr)
AU (1) AU2009203809B2 (fr)
BR (1) BRPI0907371A2 (fr)
CA (1) CA2711749A1 (fr)
CL (1) CL2009000017A1 (fr)
CO (1) CO6311108A2 (fr)
DK (1) DK2229407T3 (fr)
DO (1) DOP2010000209A (fr)
EC (1) ECSP10010333A (fr)
ES (1) ES2613152T3 (fr)
GT (1) GT201000199A (fr)
HU (1) HUE030537T2 (fr)
IL (1) IL206844A (fr)
MA (1) MA31998B1 (fr)
MY (1) MY152979A (fr)
NI (1) NI201000114A (fr)
NZ (1) NZ586590A (fr)
PA (1) PA8811601A1 (fr)
PE (1) PE20091377A1 (fr)
PL (1) PL2229407T3 (fr)
RU (1) RU2524423C2 (fr)
TN (1) TN2010000298A1 (fr)
TW (1) TW200942256A (fr)
UY (1) UY31596A1 (fr)
WO (1) WO2009087081A2 (fr)
ZA (1) ZA201003926B (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046113A1 (de) * 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
WO2007081824A2 (fr) 2006-01-06 2007-07-19 Case Western Reserve University Protéines résistantes à la fibrillation
WO2008043033A2 (fr) 2006-10-04 2008-04-10 Case Western Reserve University Insuline et analogues de l'insuline résistants à la fibrillation
AU2009203809B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
BRPI0907119A2 (pt) 2008-01-09 2015-07-14 Sanofi Aventis Deutschland Derivados de insulina tendo um perfil de ação de tempo extremamente retardado
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
WO2009132129A2 (fr) * 2008-04-22 2009-10-29 Case Western Reserve University Analogues de l’insuline spécifiques à l’isoforme
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
KR20120129875A (ko) 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
EA020537B1 (ru) 2008-12-15 2014-11-28 Зилэнд Фарма А/С Аналоги глюкагона
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
PL2370462T3 (pl) 2008-12-15 2015-01-30 Zealand Pharma As Analogi glukagonu
MX2011006314A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
JP5675799B2 (ja) * 2009-07-06 2015-02-25 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 遅効性インスリン製剤
TW201105346A (en) * 2009-07-06 2011-02-16 Sanofi Aventis Deutschland Heat-stable and vibration-stable insulin preparations
KR101853606B1 (ko) * 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
US8399407B2 (en) 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
DK2498802T3 (en) * 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
JP5866120B2 (ja) 2009-12-11 2016-02-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 塩素化アミノ酸を有するインスリン類似体
WO2011161083A1 (fr) * 2010-06-23 2011-12-29 Novo Nordisk A/S Insuline humaine contenant des liaisons disulfures supplémentaires
KR20130036290A (ko) 2010-06-23 2013-04-11 노보 노르디스크 에이/에스 추가 이황화 결합을 함유하는 인슐린 유도체
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
KR20130086343A (ko) 2010-06-24 2013-08-01 질랜드 파마 에이/에스 글루카곤 유사체
NZ603319A (en) 2010-06-24 2015-04-24 Boehringer Ingelheim Int Diabetes therapy
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
SG192038A1 (en) 2011-01-20 2013-08-30 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
PL2750699T3 (pl) 2011-08-29 2015-12-31 Sanofi Aventis Deutschland Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
US9006176B2 (en) * 2011-10-18 2015-04-14 AmideBio LLC Chemically and thermodynamically stable insulin analogues and improved methods for their production
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
MX356957B (es) 2012-07-23 2018-06-20 Zealand Pharma As Analogos del glucagon.
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
US9163073B2 (en) 2013-04-17 2015-10-20 Amidebio, Llc Chemically and thermodynamically stable insulin analogues and improved methods for their production
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
LT3057984T (lt) 2013-10-17 2018-12-27 Zealand Pharma A/S Acilinti gliukagono analogai
AU2014345569B2 (en) 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
CN112957455A (zh) 2014-01-09 2021-06-15 赛诺菲 胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
EP3091965A1 (fr) 2014-01-09 2016-11-16 Sanofi Formulations pharmaceutiques stabilisées sans glycérol d'analogues de l'insuline et/ou de dérivés de l'insuline
AU2015206890B2 (en) 2014-01-20 2019-05-23 Hanmi Pharm. Co., Ltd. Long-acting insulin and use thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
CA2961037A1 (fr) 2014-10-06 2016-04-14 Case Western Reserve University Analogues de l'insuline a chaine unique biphasique
RU2716985C2 (ru) 2014-10-29 2020-03-17 Зилэнд Фарма А/С Соединения-агонисты gip и способы
AU2015359376B2 (en) 2014-12-12 2021-09-09 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JP6989385B2 (ja) 2015-04-16 2022-01-05 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
BR112019005637A2 (pt) 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
WO2018174668A2 (fr) 2017-03-23 2018-09-27 한미약품 주식회사 Complexe d'analogue à l'insuline à affinité réduite pour le récepteur de l'insuline et son utilisation

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984696A (en) 1974-12-11 1976-10-05 Medi-Ray, Inc. Radiation guard for X-ray table
JPS6033474B2 (ja) 1978-05-11 1985-08-02 藤沢薬品工業株式会社 新規なヒアルロニダ−ゼｂｍｐ−８２３１およびその製造法
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3880346T2 (de) 1987-02-25 1993-07-29 Novonordisk As Insulinderivate.
DK257988D0 (da) * 1988-05-11 1988-05-11 Novo Industri As Nye peptider
US4923162A (en) 1988-09-19 1990-05-08 Fleming Matthew C Radiation shield swivel mount
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US5225323A (en) * 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
US5006718A (en) 1989-07-21 1991-04-09 Lenhart Mark J X-ray shield for X-ray examination table
IL95495A (en) 1989-08-29 1996-10-16 Hoechst Ag Fusion proteins their preparation and use
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5358708A (en) 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
DE4405388A1 (de) 1994-02-19 1995-08-24 Hoechst Ag Verfahren zur Herstellung von Polyalkyl-1-oxa-diazaspirodecan-Verbindungen
AR002976A1 (es) 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
AU5724996A (en) 1995-05-05 1996-11-21 Eli Lilly And Company Single chain insulin with high bioactivity
JPH11292787A (ja) 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
DE19637230A1 (de) 1996-09-13 1998-03-19 Boehringer Mannheim Gmbh Exendin-Analoga, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
ATE369146T1 (de) 1996-06-20 2007-08-15 Novo Nordisk As Insulinpreparation mit mannitol
JP3149958B2 (ja) 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
JP2001521004A (ja) 1997-10-24 2001-11-06 イーライ・リリー・アンド・カンパニー 脂肪酸−アシル化インスリン類似体
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
US5981964A (en) 1997-12-22 1999-11-09 Bruce J. McAuley Adjustable X-ray shield and on-line dosimetry system using same
DE69924232D1 (de) 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
IL137904A0 (en) 1998-02-23 2001-10-31 Neurocrine Biosciences Inc Peptide analogues of insulin and pharmaceutical compositions containing the same
CA2334222C (fr) 1998-06-05 2010-02-09 Technion Research And Development Foundation Ltd. Preparation pour nourrissons enrichie en insuline
JP2000247903A (ja) 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
JP2007204498A (ja) 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
EP1076066A1 (fr) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
DE19947456A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh C-Peptid zur verbesserten Herstellung von Insulin und Insulinanaloga
CN1245216C (zh) 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
DE10108211A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen
DE10108212A1 (de) 2001-02-20 2002-08-22 Aventis Pharma Gmbh Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
ATE443082T1 (de) * 2001-04-02 2009-10-15 Novo Nordisk As Insulinvorstufen und verfahren zu deren herstellung
CA2452044A1 (fr) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-melanges de polypeptide glp-1 et d'insuline basale
CZ2004710A3 (cs) 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
RU2357751C2 (ru) 2001-12-21 2009-06-10 Ново Нордиск Хелт Кэр Аг Жидкая композиция полипептидов фактора vii
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
ES2327328T3 (es) 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
BR0314996A (pt) 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
US20060217290A1 (en) 2003-04-29 2006-09-28 Kohn Wayne D Insulin analogs having protracted time action
DE10325567B4 (de) 2003-06-05 2008-03-13 Mavig Gmbh Strahlenschutzanordnung mit separierbarer Umhüllung
ES2373660T3 (es) 2003-11-13 2012-02-07 Novo Nordisk A/S Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
US20080248999A1 (en) 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
WO2006029634A2 (fr) 2004-09-17 2006-03-23 Novo Nordisk A/S Compositions pharmaceutiques contenant de l'insuline et un peptide insulinotropique
DE102004058306A1 (de) 2004-12-01 2006-07-27 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
US20090142338A1 (en) 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
MY146082A (en) 2005-09-14 2012-06-29 Sanofi Aventis Deutschland Cleavage of precursors of insulins by a variant of trypsin
KR101105871B1 (ko) 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
WO2007081824A2 (fr) * 2006-01-06 2007-07-19 Case Western Reserve University Protéines résistantes à la fibrillation
JP5047990B2 (ja) 2006-01-10 2012-10-10 トムソン ライセンシング ４：４：４符号化の並列な実現方法及び装置
US20070191271A1 (en) 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
EP1986674A4 (fr) 2006-02-13 2009-11-11 Nektar Therapeutics Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation
WO2007098479A2 (fr) 2006-02-21 2007-08-30 University Of Medicine And Dentistry Of New Jersey Délivrance localisée d'insuline pour guérison osseuse
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
CA2683610C (fr) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Formulations en suspension de peptides insulinotropes et leurs utilisations
WO2008145323A1 (fr) 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Formulation pharmaceutique comprenant des interférons
ES2785056T3 (es) 2007-07-02 2020-10-05 Hoffmann La Roche Un dispositivo para la administración de fármacos
CA2700662C (fr) 2007-11-01 2015-10-13 Merck Serono S.A. Formulations de lh liquides
US8710000B2 (en) 2007-11-08 2014-04-29 Novo Nordisk A/S Insulin derivative
AU2009203809B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
BRPI0907119A2 (pt) 2008-01-09 2015-07-14 Sanofi Aventis Deutschland Derivados de insulina tendo um perfil de ação de tempo extremamente retardado
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
JP2009091363A (ja) 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Ｐｔｈの安定化水溶液注射剤
KR101853606B1 (ko) 2009-07-06 2018-05-03 사노피-아벤티스 도이칠란트 게엠베하 메티오닌을 함유하는 수성 인슐린 제제
TW201105346A (en) 2009-07-06 2011-02-16 Sanofi Aventis Deutschland Heat-stable and vibration-stable insulin preparations
JP5675799B2 (ja) 2009-07-06 2015-02-25 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 遅効性インスリン製剤
KR101337322B1 (ko) 2009-11-13 2013-12-06 사노피-아벤티스 도이칠란트 게엠베하 Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
DK2498802T3 (en) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
GB201303771D0 (en) 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
AR098168A1 (es) 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina

Also Published As

Publication number Publication date
IL206844A (en) 2016-02-29
NI201000114A (es) 2011-03-15
DOP2010000209A (es) 2010-08-31
HK1149772A1 (zh) 2011-10-14
WO2009087081A3 (fr) 2009-09-17
ES2613152T3 (es) 2017-05-22
JP5694779B2 (ja) 2015-04-01
GT201000199A (es) 2013-11-18
CA2711749A1 (fr) 2009-07-16
ECSP10010333A (es) 2010-08-31
AU2009203809B2 (en) 2013-07-25
HUE030537T2 (en) 2017-05-29
RU2524423C2 (ru) 2014-07-27
US9644017B2 (en) 2017-05-09
PA8811601A1 (es) 2009-08-26
CL2009000017A1 (es) 2009-10-23
EP2229407B1 (fr) 2016-11-16
CO6311108A2 (es) 2011-08-22
RU2010133231A (ru) 2012-02-20
DK2229407T3 (en) 2017-02-27
CN102007143A (zh) 2011-04-06
IL206844A0 (en) 2010-12-30
MY152979A (en) 2014-12-15
NZ586590A (en) 2012-06-29
TW200942256A (en) 2009-10-16
CN102007143B (zh) 2015-08-26
UY31596A1 (es) 2009-08-31
EP2229407A2 (fr) 2010-09-22
WO2009087081A2 (fr) 2009-07-16
PL2229407T3 (pl) 2017-06-30
PE20091377A1 (es) 2009-09-26
TN2010000298A1 (en) 2011-11-11
AR070118A1 (es) 2010-03-17
KR20100111682A (ko) 2010-10-15
ZA201003926B (en) 2011-04-28
US20110077197A1 (en) 2011-03-31
JP2011509088A (ja) 2011-03-24
BRPI0907371A2 (pt) 2015-11-24
AU2009203809A1 (en) 2009-07-16

Similar Documents

Publication Publication Date Title
TN2010000298A1 (en) Novel insulin derivatives having an extremely delayed time-action profile
UA103015C2 (ru) Новые производные инсулина с чрезвычайно замедленным профилем время/действие
MA31997B1 (fr) Nouveaux derives de l'insuline presentant un profil d'action extremement retarde
EA201690623A1 (ru) Простациклиновые соединения, композиции и способы их использования
WO2012082056A8 (fr) Nouveau biomarqueur et ses utilisations dans le diagnostic, le traitement de l'autisme
EA201590198A1 (ru) Комплекс фактора viii с xten и белком фактора фон виллебранда и его применение (варианты)
PA8802301A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonistas del glp-1
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
WO2007112940A3 (fr) Séquence d'acides aminés dérivée de l'albumine, son utilisation pour augmenter la demi-vie de protéines thérapeutiques et d'autres composés et entités thérapeutiques, et produits de recombinaison qui la comprennent
EA201591049A1 (ru) Способы получения конъюгатов дисульфидсодержащих белков
UA107211C2 (uk) Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r)
NZ598579A (en) Oxytocin receptor agonists
EA201491049A1 (ru) Противораковый слитый белок
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
MX354005B (es) Agonistas npr-b novedosos.
EA200970981A1 (ru) Пептидная смесь в качестве стабилизатора вина
RU2013119051A (ru) Тетрапептид и средство, обладающее церебропротекторной и антиамнестической активностями
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201592019A1 (ru) Лиофилизат, содержащий циклический пептид формулы x-gqretpegaeakpwy-x
WO2012138176A3 (fr) D-aptide et aptide rétro-inverso ayant une affinité de cible maintenue et une stabilité améliorée
FR2968691B1 (fr) Dispositif de support et de fixation d'un accessoire de construction, tel qu'un crochet de gouttiere, a une couverture de toit.
JP2015519049A5 (fr)
EA201101285A1 (ru) Антагонистические пептиды к frizzled-1 и frizzled-2 рецепторам
WO2006108686A3 (fr) Agonistes bnp